Frequently Asked Questions

Ask Us Anything

Q: Where is Cell Therapeutics, Inc. incorporated? Where are CTI facilities?

A: Cell Therapeutics, Inc. was incorporated in Washington in 1991. The company headquarters are in Seattle, Washington. There are two CTI subsidiaries. Systems Medicine LLC, Scottsdale, Arizona, guides the development of our oncology products using its systems biology platform. Aequus BioPharma, Inc., a majority owned subsidiary of CTI located in Bainbridge Island, Washington, works to develop and commercialize our Genetic Polymer^™ technology.

Learn more about: Our People and Subsidiaries Contacting CTI

Q: How much has the company grown since inception?

A: Since incorporated in 1991, we have followed key strategies to build a leading biopharmaceutical company with a diversified portfolio of proprietary oncology drugs. Our research, development, acquisition, and in-licensing activities concentrate on identifying and developing new, less toxic, and more effective ways to treat cancer.

See details in: Milestones Recent Management Presentations

Q: Does CTI accept requests for charitable donations and grants?

A: We greatly value giving back to the community and believe that it takes a community-wide effort to fight cancer and create a world where those touched by it can live more productive, satisfying lives. We carefully choose mission-related patient advocacy and community programs to support with funding or volunteers based on annual budget constraints.

Learn more about: CTI Community Involvement Unrestricted Education Grants - this program is not taking applications at this time

Q: I’m a vendor who would like to contact CTI. How should I do that?

A: Call our Reception desk at 206.282.7100, and your call will be directed to the appropriate department.

Q: Where can I find the most recent data you have presented?

A: You’ll find data presented at recent medical and scientific conferences on our Investor Updates page. Recent 10K and 10Q filings with the SEC include summaries of our drug development status, and our executive management discusses these topics in our webcasts.